Pharma Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angina
U.S. FDA approves Ranexa
February 27th, 2006
CV Therapeutics, Inc., (CVTX) announced that the U.S. Food & Drug Administration (FDA) has approved Ranexa (ranolazine extended-release tablets). The approved indication is as follows: Ranexa is indicated for the treatment of chronic angina. Ranexa should be reserved for patients who have not achieved an adequate response with other antianginal drugs. Ranexa should be used in combination with amlodipine, beta blockers, or nitrates. The effect on angina rate or exercise tolerance appeared to be smaller in women than men. According to the company, the approval of Ranexa marks the first new pharmaceutical approach to treat angina in more than 20 years...
Source: Pharma Business Week (2006-02-27)
|
